Login
$PMN
$3.25 -$0.06 (1.81%) After hours

$PMN SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

PRECISE-AD Phase 1b clinical trial in Alzheimer’s patients remains on track for unblinded 12-month topline data in the first quarter of 2027, including full safety, biomarker and cognitive outcomes data

12 Nov 2026 SCHEDULE 13G
12 Nov 2026 8-K: Regulation FD Disclosure

Copyright 2026, ProMIS Neurosciences Inc., Non-confidential L E G A L D I S C L O S U R E S Forward-Looking Statements & Disclaimers This slide deck may contain certain forward-looking information and “forward-looking statements” that ar...

06 Nov 2026 Form 4: Williams Eugene, Director

Bought 26,500 shares ($90.9K)

03 Nov 2026 Form 4: Williams Eugene, Director

Bought 1,316 shares ($5.25K)

03 Nov 2026 Form 4: Cashman Neil, Director

Bought 10,000 shares ($38.6K)

06 Oct 2026 Form 4: Rubino Ivana, Chief Commercial Officer

Granted 80,000 Option (right to buy)

06 Oct 2026 Form 3: Rubino Ivana, Chief Commercial Officer

No securities owned

14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 8-K: Results of Operations and Financial Condition

Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalit...

13 Aug 2026 10-Q
13 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 Form 4: Kaplan Johanne, Chief Development Officer

Bought 2,280 shares ($30.3K)

28 Jul 2026 8-K: Regulation FD Disclosure; Other Events

PRECISE-AD PMN310 · PHASE 1b BLINDED 6-MONTH INTERIM ANALYSIS Safety & Biomarker Assessment Update Blinded Interim Analysis Topline results expected Q1 2027 1

29 May 2026 S-8
22 May 2026 Form 4: Wyman William W, Director

Granted 16,500 Option (right to buy)

22 May 2026 Form 4: Williams Eugene, Director

Granted 16,500 Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support